Department of Health and Human Services, through National Institutes of Health, awarded Mucommune LLC of Durham, NC $2,292,701 under the SBIR program, with work starting 2025-09-16 and running to 2027-08-31. It is one of 3 SBIR and STTR awards Mucommune LLC received in the last two years, $5,356,553 in all. Each figure links to the federal record.
The award
| Recipient | Mucommune LLC (Durham, NC) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Amount obligated | $2,292,701 |
| Period of performance starts | 2025-09-16 |
| Period of performance ends | 2027-08-31 |
| Award number | R44CA310402 (grant, CFDA 93.395) |
| Assistance listing | 93.395, Cancer Treatment Research |
| Place of performance | Morrisville, Wake County, NC |
| Signed | 2025-09-15 |
| Recipient registry id (UEI) | NWVPL2L4JMN8 |
Want the whole picture on Mucommune LLC?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mucommune LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mucommune LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
In vivo engineering of multifaceted B7H3.car-t cells for cellular immunotherapy of pancreatic ductal adenocarcinoma - project summary t-cells modified with chimeric antigen receptor against unique cancer antigens i.e., c
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-13 | Continuation | 001 | $1,146,083 |
| 2026-01-09 | Revision | 000 | $0 |
| 2025-09-15 | New | 000 | $1,146,618 |
SBIR: In vivo engineering of multifaceted B7H3.car-t cells for cellular immunotherapy of pancreatic ductal adenocarcinoma - project summary t-cells modified with chimeric antigen receptor against unique cancer antigens i.e., car-t, represent a promising form of immunotherapy for cancer, but are currently limited by production time and costs to prepare the engineered t-cells ex vivo, as well as by modest efficacy against solid cancers due to poor tumor penetration. Rather than harvesting, activating, transducing, and expanding t-cells ex vivo, we believe direct engineering of car-t cells in vivo, by transducing circulating t-cells with high specificity, will reduce the time and cost of car-t therapy while also maximizing t-cell function by eliminating extended cultures in vitro. Mucommune has recently in-licensed a platform that enables exceptionally potent yet highly specific transduction of circulating t-cells, without first requiring t-cell activation, by combining both virological and chemical approaches. Specifically, IT utilizes a lv system incorporating the nipah virus fusion protein with its native tropism ablated and retargeted via ANTI-CD3 scfv, then formulates the resulting nipah lv (nlv) with a proprietary combo of transduction enhancers. To date, we have shown that this new system can specifically transduce non-activated t-cells among circulating pbmcs in vivo, gene ...
From the federal award record.
Other SBIR and STTR awards to Mucommune LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-11 | Department of Health and Human Services | SBIR | $1,006,467 | In vivo engineering of dual CD19/CD138 car-t cells for treatment of systemic lupus erythem (record) |
| 2025-09-11 | Department of Health and Human Services | SBIR | $2,057,385 | In vivo engineering of B7-H3.car-t cells for ovarian cancer therapy - project summary t-ce (record) |
Every other federal award to Mucommune LLC on record
The federal register lists 23 other awards to the same registry id (UEI NWVPL2L4JMN8), $25,091,932 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-09-25 | National Institutes of Health | $1,163,587 | Ind-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ring - summary n (R44HD121291) |
| 2026-09-07 | National Institutes of Health | $1,860,006 | Preclinical and clinical development of on-demand and sustained non-hormonal contraceptives based on highly mu (P50HD123737) |
| 2025-09-15 | National Institutes of Health | $2,299,857 | Fast dissolving MM008 tablet for instant on-demand non-hormonal contraception - project summary nearly half of (R44HD118898) |
| 2025-09-15 | National Institutes of Health | $359,608 | Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity - p (R43DK143890) |
| 2025-09-12 | National Institutes of Health | $409,732 | Development of MM010, a peg-specific intervention that blocks allergic response and restores effective repeat (R43CA310433) |
| 2025-08-21 | National Institutes of Health | $619,346 | Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and pr (R43AI189008) |
| 2025-07-01 | National Institutes of Health | $306,183 | Sustained release of VRC07 from capsule-intravaginal ring for preventing HIV transmission (75N93025C00021) |
| 2025-06-23 | National Institutes of Health | $2,017,780 | Ind-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic aci (R44AI192170) |
| 2025-03-25 | National Institutes of Health | $550,000 | Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception - summary nearly h (R33HD117428) |
| 2025-03-25 | National Institutes of Health | $380,692 | Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception - summary nearly h (R61HD117428) |
| 2024-01-22 | National Institutes of Health | $582,916 | Ind-enabling development of MM010, a peg-specific intervention that blocks allergic response and restores repe (R43AI181354) |
| 2023-04-01 | National Institutes of Health | $306,483 | Highly acidifying intravaginal rings with lactobacillus probiotics to treat bacterial vaginosis - abstract mil (R43AI177160) |
| 2022-09-19 | National Institutes of Health | $2,067,567 | Ind?enabling development of mm?008 ivr, an antibody-based nonhormonal contraceptive intravaginal ring - summar (R44HD107824) |
| 2022-09-01 | National Institutes of Health | $306,500 | Fast dissolving antibody tablets for preventing vaginal hsv transmission - project summary despite immense eff (R43AI172654) |
| 2022-07-01 | National Institutes of Health | $277,713 | Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a n (R43HD108822) |
| 2021-03-04 | National Institutes of Health | $2,380,033 | SBIR: In vivo validation and ind-enabling development of MM004, a bispecific inhaled immunotherapy for rsv and (R44AI157661) |
| 2021-03-01 | National Institutes of Health | $306,500 | Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks - (R43AI157652) |
| 2020-09-15 | National Institutes of Health | $972,804 | In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring (R44HD100231) |
| 2019-09-14 | National Institutes of Health | $1,705,343 | Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs - summary ne (R33HD099747) |
| 2019-09-14 | National Institutes of Health | $522,711 | Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs (R61HD099747) |
| 2019-08-19 | National Institutes of Health | $1,774,918 | Development of respiraclear for targeted mucosal treatment of rsv infections (R44AI141054) |
| 2018-09-17 | National Institutes of Health | $1,926,969 | Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal prote (R44HD097063) |
| 2018-08-20 | National Institutes of Health | $1,994,684 | In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of rsv (R44AI138728) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Mucommune LLCLook up Mucommune LLC first. Finding the company and seeing how much is on record uses no credits.
Look up Mucommune LLCWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.